B-Scientists
FDA-approved CRISPR treatment for sickle cell disease - seeking hematologists
Suggested angles
Explain the clinical trial data that led to FDA approval—specifically how the treatment affects hemoglobin levels and vaso-occlusive crisis frequency in the patient population your practice serves
Address the patient selection criteria and genetic testing requirements hematologists need to implement in their clinics to identify eligible sickle cell patients, including discussion of pre-treatment assessments
Discuss the post-treatment monitoring protocols and long-term follow-up expectations for patients who receive the CRISPR therapy, including what hematologists should communicate to patients about realistic timelines for symptom improvement
B-Scientists readers want actionable clinical details: pitch yourself as someone who can explain what hematologists need to know to implement this treatment in their practice.
Know someone perfect for this?
Share this page or forward the digest email.
Get opportunities like this daily
Subscribe to the SignalDesk digest — free and matched to your interests.
Subscribe at signaldesk.cc